Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FCPR03 is a selective inhibitor of phosphodiesterase 4 (PDE4) with IC50s of 31 nM, 47 nM, and 60 nM for PDE4B1, PDE4D7, and PDE4 catalytic domain, respectively. FCPR03 has neuroprotective, anti-inflammatory, and antidepressant-like effects.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 97.00 | |
5 mg | In stock | $ 247.00 | |
10 mg | In stock | $ 397.00 | |
25 mg | In stock | $ 663.00 | |
50 mg | In stock | $ 945.00 | |
100 mg | In stock | $ 1,280.00 | |
500 mg | In stock | $ 2,570.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 272.00 |
Description | FCPR03 is a selective inhibitor of phosphodiesterase 4 (PDE4) with IC50s of 31 nM, 47 nM, and 60 nM for PDE4B1, PDE4D7, and PDE4 catalytic domain, respectively. FCPR03 has neuroprotective, anti-inflammatory, and antidepressant-like effects. |
Targets&IC50 | PDE4D7:47 nM (IC50), PDE4B1:31 nM (IC50), PDE4 catalytic domain:60 nM (IC50) |
In vitro | FCPR03 displays at least 2100-fold selectivity over other PDEs (PDE1-3 and PDE5-11). In HT-22 cells, FCPR03 (5, 10, and 20 μM) increases cell viability under the oxygen-glucose deprivation (OGD) induced condition in a dose-dependent manner. FCPR03 (20 μM) increases the levels of phosphorylated AKT, GSK-3β, and β-catenin. FCPR03 (20 μM) protects against OGD-induced cellular apoptosis in both HT-22 cells and cortical neurons. The levels of mitochondrial membrane potential (MMP) and ROS are restored by FCPR03. FCPR03 (10 μM) shows significant protective effects[2]. |
In vivo | In adult male Sprague-Dawley rats following cerebral ischemia-reperfusion, FCPR03 increases the levels of phosphorylated AKT, GSK3β and β-catenin within the ischemic penumbra. In rats following MCAO, FCPR03 (1.25, 2.5, 5 mg/kg; i.p.) reduces the infarct volume and improves neurobehavioral outcomes[2]. |
Molecular Weight | 299.31 |
Formula | C15H19F2NO3 |
CAS No. | 1917347-65-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 95 mg/mL (317.40 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
FCPR03 1917347-65-9 Metabolism PDE antidepressant-like PDE4B1 PDE4D7 FCPR-03 PDE4 neuroprotective ischemic AKT GSK3β FCPR 03 inhibit anti-inflammatory Phosphodiesterase (PDE) β-catenin Inhibitor stroke inhibitor